Lexology February 15, 2024
Morgan, Lewis & Bockius LLP

It is hard to believe that we are already in February and it has been a month since the 42nd Annual JP Morgan Healthcare Conference in San Francisco wrapped. It was a packed four days in which the major players in the life sciences industry gathered to make deals, form relationships, and discuss upcoming trends for the pharmaceutical and biotechnology industry.

For those who may not have attended or for whom the week was a blur (or distant memory), below are some key takeaways in the areas of FDA regulation and corporate transactions from some of the events surrounding the conference. This includes an event held by STAT News during which the Director of the FDA Center for Biologics Evaluation...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Conferences / Podcast, FDA, Govt Agencies, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Deep learning uncovers gene targets and potential drugs to slow brain aging
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
Common Trends in GLP-1 Use Amid Increased Indications
Ensitrelvir Shows Promise Preventing COVID-19 Post Exposure
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial

Share This Article